Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
Conditions
- Metastatic Castration-Resistant Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
- DRUG: Lutetium Lu 177 Vipivotide Tetraxetan
- PROCEDURE: Cell-free Circulating Tumor DNA Assay
- PROCEDURE: Computed Tomography
- DRUG: Docetaxel
- PROCEDURE: PSMA PET Scan
- PROCEDURE: Single Photon Tomography and Computed Tomography Scan
- PROCEDURE: Biospecimen Collection
Sponsor
University of Washington
Collaborators